Pharmaceutical

China conditionally approves Hutchmed’s Tazverik for follicular lymphoma

NMPA has granted conditional approval for Hutchmed’s Tazverik to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL)

Mar 23, 2025 - 06:00
China conditionally approves Hutchmed’s Tazverik for follicular lymphoma
NMPA has granted conditional approval for Hutchmed’s Tazverik to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL)
Read the original article

Tags:

Previous Article

New Device Facilitates Direct Communication Between Multiple Quantum Processors

Next Article

European agencies catch up with speedier regulatory pathways for CGTs in the US

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Signal: Nimbus raises $210m to foster drug discovery plans

Signal: Nimbus raises $210m to foster drug discovery plans

Sep 7, 2023

Cystic fibrosis: global clinical trials landscape and treatments

Cystic fibrosis: global clinical trials landscape and t...

May 25, 2024

Eloxx moves ahead with plans with gene therapy for rare kidney disorder

Eloxx moves ahead with plans with gene therapy for rare...

Sep 9, 2023